Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00692809
Other study ID # SKS/LTBI/07
Secondary ID
Status Recruiting
Phase N/A
First received June 5, 2008
Last updated September 14, 2009
Start date July 2008
Est. completion date March 2010

Study information

Verified date June 2008
Source Ministry of Science and Technology, India
Contact Surendra K Sharma, M.D., Ph.D
Phone 26594415
Email surensk@gmail.com
Is FDA regulated No
Health authority India: Institutional Review Board
Study type Observational

Clinical Trial Summary

HIV induced altered representation and function of regulatory T cell subsets (NKT and Treg cells) impair the protective T cell response against M.tuberculosis and disrupts LTBI, thus facilitates faster progression and development of severe forms of clinical TB in HIV-TB co-infection.


Description:

During the natural course of HIV disease, emergence of opportunistic infection not only imposes morbidity on HIV-TB co-infected patients, but also facilitates viral replication causing faster disease progression. Tuberculosis, being the commonest among the opportunistic infections among HIV infected persons deserves special attention. Moreover, disruption of latency of TB infection (LTBI) with development of more severe clinical forms at relatively early stage of HIV disease when CD4 count still remains above 300/ul, makes TB a unique opportunistic infection and negatively influence the outcome of dual infection.This is suggestive of impairment of some critical immune function involving relatively less frequent fine T cell subsets with functional hierarchy over bulk T cells, so as to weaken the immune containment of LTBI resulting in reactivation of M. tuberculosis and manifestation of severe forms of TB.HIV has recently been reported to preferentially infect, destroy and incapacitate two key immune-regulatory T cell subsets, namely NKT and Treg cells.Therefore, studying them along the course of HIV disease and impact of their changes on the function of effector T cells directed against M.tuberculosis is important.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

HIV infected +LTBI group:

- Patient of either sex between 18-65 years of age

- All the patients should be HIV ELISA test positive irrespective of CD4 count and presence of other opportunistic infections Antiretroviral drug naive HIV patients

- No past history of TB

- Patients should be either tuberculin test positive (> 5mm) or interferon gamma release assay positive

- Written informed consent to participate in the study given by participants or legal guardian

- Patients able to comply with instructions and come back for a regular follow up

HIV infected + Clinical TB group:

- Patient of either sex between 18-65 years of age

- All the patients should be HIV ELISA test positive irrespective of CD4 count and presence of other opportunistic infections

- In PTB group, patient should be two sputum smear positive out of three consecutive samples

- In EPTB group, diagnosis of TB will be:

- Definitive -Culture confirmed

- Probable -Histopathological or radiological -Clinical features and response to anti TB treatment (ATT)

- Possible TB -Clinical feature and response to anti TB treatment (ATT)

- Written informed consent to participate in the study given by participants or legal guardian

- Patients able to comply with instructions and come back for a regular follow up

HIV negative Clinical TB group:

- Patients of either sex between 18-65 years of age who are permanent resident of Delhi

- All patients should be HIV ELISA negative

- In PTB group, patients should be two sputum smear positive (at least 1+) out of three consecutive samples

- In EPTB group, diagnosis of TB will be:

- Definitive -Culture-confirmed

- Probable -Histopathological or radiological -Clinical features and response to anti-TB treatment (ATT)

- Possible TB -Clinical features and response to anti-TB treatment (ATT)

- Written informed consent to participate in the study given by participants or legal guardian

- Patients able to comply with instructions and come back for a regular follow up

Normal controls:

- Persons of either sex between 18-65 years of age who are permanent resident of Delhi

- Written informed consent to participate in the study given by participants or legal guardian

- Person should not have past history of TB

- Mantoux test negative (< 10mm)

- Chest-X-ray normal

- Hemogram normal

- Renal and liver functions normal

- Hepatitis viral markers normal

- No clinical evidence of malnutrition

- HIV ELISA negative

Exclusion Criteria:

HIV infected +LTBI group:

- Pregnant and lactating females

- Patients who are getting steroid therapy

- Transplant patients, diabetes mellitus or malignancy, chronic renal failure or liver diseases

- Currently receiving cytotoxic therapy, or have received it within the last 3 months

- Terminally ill as per treating clinician's judgment

- Patient from outside Delhi and migrants

HIV infected + Clinical TB group:

- Category II and multidrug-resistant pulmonary tuberculosis

- Pregnant and lactating females

- Patients who are getting steroid therapy

- Transplant patients, diabetes mellitus or malignancy, chronic renal failure or liver diseases

- Currently receiving cytotoxic therapy, or have received it within the last 3 months

- Terminally ill patient as per treating clinician's judgment

- Patients from outside Delhi and migrants

HIV negative Clinical TB group:

- Category II and multi drug-resistant pulmonary tuberculosis

- Patients who are getting steroid therapy

- Transplant patients, diabetes mellitus or malignancy, chronic renal failure or liver disease

- Currently receiving cytotoxic therapy, or have received it within the last 3 months

- Terminally ill patient as per treating clinician's judgment

- Patients unwilling to comply with the study procedures or those with history of alcohol or drug abuse

Normal controls:

- Transplant patients, diabetes mellitus or malignancy

- Patients unwilling to comply with the study procedures or those with history of alcohol or drug abuse

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
India All India Institute of Medical Sciences New Delhi Delhi

Sponsors (2)

Lead Sponsor Collaborator
Ministry of Science and Technology, India Indian Council of Medical Research

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Precise component(s) of T cell response against M.tuberculosis compromised by HIV infection which leads to the development of severe forms of clinical tuberculosis. 5 months No
Secondary Elucidation of critical events of the cellular and molecular interactions that would be useful for developing newer therapeutic strategies and vaccination. 5 months No
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2